01—Abstract
Summary
Summary of the 8-K filed August 1, 2025. Cited figures are marked; the original filing is the authoritative source.
ResMed Inc. filed a Current Report on Form 8-K under Item 5.02(b), disclosing a senior executive departure.
The filing states that on July 28, 2025, Bobby Ghoshal, the company's chief commercial officer for its residential care software business ("RCS"), notified ResMed that he intends to resign effective August 1, 2025. The filing says Mr. Ghoshal is leaving to pursue an opportunity as chief operating officer of a software company in an industry that is not competitive with ResMed's. The filing does not name a successor or describe any transition arrangements.
The report was signed on July 31, 2025 by Brett Sandercock, Chief Financial Officer. The filing contains no financial results or other financial data.
02—Key points
Key Highlights
- Bobby Ghoshal, chief commercial officer of the residential care software business ("RCS"), notified ResMed of his intent to resign on July 28, 2025.
- His resignation is effective August 1, 2025.
- Mr. Ghoshal is leaving to become chief operating officer of a software company in a non-competitive industry.
- The disclosure is made under Item 5.02(b) of Form 8-K, which covers departures of certain officers.
- The filing does not name a successor or describe interim leadership arrangements for the RCS commercial role.
- The filing contains no financial results, guidance, or other financial metrics.
03—Questions
Frequently Asked Questions
Who is leaving ResMed and what was his role?
Bobby Ghoshal was chief commercial officer of ResMed's residential care software business ("RCS"), according to the filing.
When is the departure effective?
The filing states that Mr. Ghoshal intends to resign effective August 1, 2025. He notified the company of this intent on July 28, 2025.
Where is he going?
The filing says he will pursue an opportunity as chief operating officer of a software company in a non-competitive industry from ResMed's.
Does the filing name a replacement?
No. The filing does not identify a successor or describe any interim arrangements for the role.
Does this filing report any financial results?
No. The filing addresses only the executive departure and is signed by Chief Financial Officer Brett Sandercock. It contains no financial figures.
04—Continue